Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.


Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.


Lipigon Pharmaceuticals today announced that it has entered into a research collaboration with AstraZeneca to conduct joint research to identify drug candidates that promote the stabilization of Lipoprotein Lipase (LPL) and may have utility in the treatment of lipid disorders and cardiovascular disease.


15 mars, 2023, Pressmeddelande

Lipigon rapporterar säkerhetsdata för högsta doseringsgruppen i Lipisense-studie

Lipigon Pharmaceuticals AB ("Lipigon") presenterade i dag ytterligare positiva säkerhetsresultat frå...

13 mars, 2023, Pressmeddelande

Lipigon presenterar på Stora Aktiedagen den 15 mars

På onsdag den 15 mars deltar Lipigon Pharmaceuticals på Stora Aktiedagen i Stockholm. Bolagets vd St...

28 februari, 2023, Pressmeddelande

Kallelse till extra bolagsstämma i Lipigon Pharmaceuticals AB

Aktieägarna i Lipigon Pharmaceuticals AB, 556810-9077, ("Bolaget") kallas härmed till extra b...